Omnicell ( (OMCL) ) has released its Q4 earnings. Here is a breakdown of the information Omnicell presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Omnicell, Inc. is a company that focuses on transforming pharmacy and nursing care delivery through a comprehensive portfolio of robotics, smart devices, intelligent software workflows, and expert services, aiming to enhance medication management across healthcare settings. The company recently announced strong financial results for the fourth quarter and full fiscal year 2024, surpassing its previously issued guidance. Omnicell reported total revenues of $307 million for the fourth quarter, reflecting a 19% increase compared to the same period in 2023, and $1.112 billion for the full year, which was slightly lower than the previous year. The company returned to GAAP profitability with a net income of $16 million for the fourth quarter, a significant improvement from the net loss in the prior year. Non-GAAP net income also saw a substantial increase to $28 million for the quarter. Omnicell’s bookings grew by 8% year-over-year, driven by XT Series upgrades and XTExtend bookings. Moving forward, Omnicell focuses on long-term revenue growth, consistent GAAP profitability, and innovation in medication management. The company remains committed to its strategic priorities and aims to bring new products and services to market, with optimistic projections for fiscal year 2025.
